Outlook Therapeutics Inc. (OTLK) is on the brink of a make-or-break juncture that could pave the way for unprecedented growth and innovation within the company. With the FDA's Prescription Drug User Fee Act (PDUFA) goal date set for December 31, 2025, the spotlight is firmly on the company's leading product candidate, ONS-5010/LYTENAVA (bevacizumab-vikg).
This treatment is currently undergoing its final review for potential approval in addressing wet age-related macular degeneration (AMD).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com